Filter Results
:
(920)
Show Results For
-
All HBS Web
(920)
- People (2)
- News (61)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (643)
Show Results For
-
All HBS Web
(920)
- People (2)
- News (61)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (643)
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- January 2014 (Revised June 2015)
- Case
Amgen Inc.: Pursuing Innovation and Imitation? (A)
By: Ian W. Mackenzie
Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:...
View Details
Mackenzie, Ian W. "Amgen Inc.: Pursuing Innovation and Imitation? (A)." Harvard Business School Case 714-424, January 2014. (Revised June 2015.)
- 12 Nov 2013
- First Look
First Look: November 12
GlaxoSmithKline: Sourcing Complex Professional Services Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional...
View Details
Keywords:
Sean Silverthorne
- October 2021 (Revised October 2022)
- Case
The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide...
View Details
Keywords:
Opioids;
Drug;
Investors;
Shareholder Activism;
Investment Activism;
Executive Compensation;
Corporate Accountability;
Corporate Governance;
Governance Compliance;
Governance Controls;
Risk Management;
Corporate Social Responsibility and Impact;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Legal Liability;
Distribution Industry;
Distribution Industry;
Distribution Industry;
United States;
West Virginia;
Tennessee;
Ohio;
Pennsylvania
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen." Harvard Business School Case 122-014, October 2021. (Revised October 2022.)
- January 2017
- Case
The Six CEOs of Tyco International Ltd.
By: John R. Wells and Gabriel Ellsworth
In September 2016, Johnson Controls, Inc. completed the acquisition of Tyco International PLC, a $9.9 billion business with operating profits of $884 million. The purchase consideration was $14.4 billion. Although the deal was billed as a merger, Ireland-based Tyco...
View Details
Keywords:
Tyco;
Dennis Kozlowski;
Edward Breen;
Fire Safety;
Fire Protection;
Security;
Packaging;
Securities And Exchange Commission;
Fraud;
Accounting;
Accounting Audits;
Earnings Management;
Financial Statements;
Goodwill Accounting;
Acquisition;
Mergers and Acquisitions;
Business Conglomerates;
Business Divisions;
Business Exit or Shutdown;
Business Growth and Maturation;
Business Headquarters;
Business Model;
Business Organization;
For-Profit Firms;
Restructuring;
Crime and Corruption;
Engineering;
Applied Optics;
Chemicals;
Construction;
Metals and Minerals;
Ethics;
Finance;
Cash Flow;
Public Equity;
Stock Options;
Financing and Loans;
Initial Public Offering;
Profit;
Revenue;
Geographic Location;
Geographic Scope;
Global Range;
Globalized Firms and Management;
Multinational Firms and Management;
Corporate Accountability;
Corporate Disclosure;
Health Care and Treatment;
Business History;
Executive Compensation;
Selection and Staffing;
Courts and Trials;
Lawfulness;
Lawsuits and Litigation;
Business or Company Management;
Goals and Objectives;
Growth and Development Strategy;
Market Entry and Exit;
Public Ownership;
Problems and Challenges;
Strategy;
Business Strategy;
Competition;
Competitive Strategy;
Competitive Advantage;
Consolidation;
Corporate Strategy;
Diversification;
Expansion;
Horizontal Integration;
Value;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Republic of Ireland;
Switzerland;
Bermuda;
United States;
New Hampshire
Wells, John R., and Gabriel Ellsworth. "The Six CEOs of Tyco International Ltd." Harvard Business School Case 717-459, January 2017.
- Web
General Management Awards & Honors - Faculty & Research
Medical School. Regina E. Herzlinger: Named one of the 40 Smartest People in Healthcare by Becker’s Hospital Review in 2014. Regina E. Herzlinger: Received the 2014 Beatrice D. Ellerin Award from the HBS Health Industry Alumni. The...
View Details
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that...
View Details
- 13 Oct 2009
- Research & Ideas
7 Lessons for Navigating the Storm
take the global economic crisis, or any other crisis, and turn it into an opportunity to transform your markets and your company? Here are 7 steps to keep your organization focused on winning the depth of the crisis: Step 1: Rethink your View Details
Keywords:
by Martha Lagace
- September–October 2020
- Article
Social-Impact Efforts That Create Real Value
By: George Serafeim
Until the mid-2010s few investors paid attention to environmental, social, and governance (ESG) data—information about companies’ carbon footprints, labor policies, board makeup, and so forth. Today the data is widely used by investors. How can organizations create...
View Details
Keywords:
Sustainability;
Sustainability Management;
ESG;
ESG (Environmental, Social, Governance) Performance;
ESG Disclosure;
ESG Disclosure Metrics;
ESG Ratings;
ESG Reporting;
Social Impact;
Impact Measurement;
Social Innovation;
Purpose;
Corporate Purpose;
Corporate Social Responsibility;
Strategy;
Social Enterprise;
Society;
Accounting;
Investment;
Environmental Sustainability;
Climate Change;
Corporate Strategy;
Mission and Purpose;
Corporate Social Responsibility and Impact;
Financial Services Industry;
Chemical Industry;
Technology Industry;
Consumer Products Industry;
Pharmaceutical Industry;
North America;
Europe;
Japan;
Australia
Serafeim, George. "Social-Impact Efforts That Create Real Value." Harvard Business Review 98, no. 5 (September–October 2020): 38–48.
- Web
Strategy Awards & Honors - Faculty & Research
in the future." 2022 Alexander J. MacKay: Awarded the 2022 Robert F. Lanzillotti Prize for Best Paper in Antitrust Economics at the International Industrial Organization Conference for "Rising Markups and the Role of Consumer Preferences"...
View Details
- Web
Medical Devices | Baker Library | Bloomberg Center | Harvard Business School
Financial data on equities, indices, currencies, commodities and futures. BI for global medical devices industry data, news, and analysis. Frost & Sullivan https://www.library.hbs.edu/find/databases/frost-sullivan Reports and market...
View Details
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- Web
2022 Reunion Presentations - Alumni
Senior Lecturer Kristin W. Mugford (MBA 1993) + More Info – Less Info Over the last decade, firms have begun to recognize the power of gender diversity and have worked to actively hire and retain more women. While we see improved diversity at junior levels, View Details
- June 2023
- Supplement
Roche: ESG and Access to Healthcare
By: George Serafeim
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Health Industry;
Pharmaceutical Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George. "Roche: ESG and Access to Healthcare." Harvard Business School Multimedia/Video Supplement 123-713, June 2023.
- April 2011 (Revised April 2015)
- Case
Cipla 2011
By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.
View Details
Keywords:
Leadership;
Leading Change;
Leadership Style;
Management Teams;
Governance Compliance;
Corporate Strategy;
Pharmaceutical Industry
Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)
- 31 Jan 2014
- News
Body, Heal Thyself
for the development and exclusive use of the mRNA technology to treat cardiovascular, renal, and metabolic diseases as well as cancer. "It is one of the largest-ever initial payments in a pharmaceutical View Details
- April 2009
- Case
Merck: Managing Vioxx (A)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient...
View Details
Keywords:
Ethics;
Crisis Management;
Reputation;
Decision Choices and Conditions;
Customers;
Business or Company Management;
Cost vs Benefits;
Corporate Accountability;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Customer Focus and Relationships;
Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (A)." Harvard Business School Case 109-080, April 2009.
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it...
View Details
Keywords:
Representation;
Racial Disparity;
Health Testing and Trials;
Race;
Equality and Inequality;
Innovation and Invention;
Pharmaceutical Industry
Alsan, Marcella, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein, and Heidi L. Williams. "Representation and Extrapolation: Evidence from Clinical Trials." Quarterly Journal of Economics 139, no. 1 (February 2024): 575–635.
- June 2014 (Revised September 2014)
- Case
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch and Carin-Isabel Knoop
To create the world's healthiest workforce, diversified health care giant Johnson & Johnson (J&J) mandated participation in its "Culture of Health" program globally, customized by location, culture, and specific health needs to offer prevention-focused education,...
View Details
Keywords:
Healthcare;
Employee Motivation;
Transformation;
Ethics;
Health;
Human Resources;
Leadership;
Management;
Personal Development and Career;
Problems and Challenges;
Strategy;
Health Industry;
Health Industry;
Health Industry;
North and Central America;
Middle East;
Latin America;
Europe;
Asia
Quelch, John A., and Carin-Isabel Knoop. "Johnson & Johnson: The Promotion of Wellness." Harvard Business School Case 514-112, June 2014. (Revised September 2014.)
- Research Summary
Overview
By: Andy Wu
How can technology entrepreneurs build competitive advantage from the ground up? Professor Andy Wu conducts scholarly research and develops course materials that document how technology entrepreneurs can (1) organize for innovation to create new market opportunities...
View Details
Keywords:
Strategy;
Entrepreneurship;
Venture Capital;
Growth Management;
Organizational Design;
Organizational Structure;
Technology Platform;
Technological Innovation;
Information Technology Industry;
Information Technology Industry;
Information Technology Industry;
Information Technology Industry;
Information Technology Industry;
United States;
China;
Southeast Asia;
South Asia